ALBANY (AP) — New York state is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine.
An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.
It will involve Epidiolex, an investigational medication that uses cannabidiol, a marijuana extract that doesn’t get users high. It could help children with rare forms of epilepsy such as Dravet and Lennox-Gastaut syndromes.
“Young New Yorkers battling these diseases deserve treatments that work for them, and by investigating the merits of cannabidiol we are pushing the boundaries of modern medicine and working to fundamentally improve the quality of life for those children,” Cuomo said Tuesday.
Dravet syndrome is a rare genetic disorder typically untreatable by anti-epileptic drugs. It can be fatal. Lennox-Gastaut syndrome, another rare form of childhood-onset epilepsy, is characterized by different types of seizures multiple times a day and cognitive dysfunction. To be eligible for the trial, the children would have to show signs that their current medication is not working.